45° Good Morning
45° Good Morning

Enzo BioChem posts $10.3M quarterly loss

Enzo BioChem Inc., Manhattan

Biotechnology developer; parent company of Enzo Clinical Labs, of Farmingdale

Second Quarter: Ended Jan. 31

Net revenue: Rose to $23.2 million from $21 million in the year-ago quarter.

Net income: Loss of $10.3 million, compared to a loss of $7.7 million in the same quarter last year.

Company statement: "The fiscal second quarter reflected another quarter of improved operating results, excluding unusually high proxy-related costs and a one-time payment to a former officer to settle litigation and the related legal costs," Barry Weiner, the company president, said in a statement. "Margin improvement reflected a more favorable mix of products at Enzo Life Sciences and a higher percentage of esoteric testing at Enzo Clinical Labs."


We're revamping our Comments section. Learn more and share your input.

More news